and extracts the following text as a script body — the dev server then fails its dependency scan with `Expected ";" but found "non"` from the words "non-allowlisted hosts", which breaks e2e. So, what this buys, so nobody reads more or less into it: blocks external `script src=` from non-allowlisted hosts blocks injected inline scripts — each one is pinned by hash blocks fetch/XHR/WebSocket exfiltration (connect-src allowlist) blocks form-action, base-uri, object-src vectors does not stop image-based exfiltration — img-src must allow https: because event media comes from arbitrary publishers' og:image The cost of hashing is that an inline script edited after the hashes are computed is silently refused by the browser. That is why the violation reporter below exists: report-uri/report-to are ignored in a meta element and Pages serves no CSP header, so violations are caught in-page and sent to PostHog instead (src/lib/csp-report.ts, #241). frame-ancestors is deliberately NOT in this string: it is ignored in a meta element and browsers log a warning about it on every page load. It lives in public/_headers instead, ready for a CDN in front of Pages. X-Frame-Options (set there too) is the clickjacking control that actually applies today. */ }
partnership high confidence

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery for Diabetes and Obesity

| AI for Good

Novo Nordisk, the world's leading diabetes and obesity drug maker, announced on April 14 a strategic partnership with OpenAI to integrate advanced AI throughout its drug development pipeline. CEO Mike Doustdar stated the collaboration enables the company to 'analyse datasets at a scale that was previously impossible,' dramatically accelerating the identification of drug candidates for chronic diseases like diabetes and obesity — conditions affecting over 800 million people globally. The partnership will apply OpenAI's large language and reasoning models to molecular biology datasets, clinical trial data analysis, and biomarker identification. This follows a trend of major pharmaceutical companies forming AI-first drug discovery alliances, though the Novo Nordisk-OpenAI partnership is notable for targeting diseases affecting primarily lower- and middle-income countries and populations in the Global South where affordable treatment remains inaccessible.

Media

Novo Nordisk and OpenAI partner to use AI for accelerating drug discovery for chronic disease
Novo Nordisk and OpenAI partner to use AI for accelerating drug discovery for chronic disease — Euronews

Sources

View full AI for Good dashboard